| Anika: A Hidden Biotech Buy With a market value sub-$100 million, Anika Therapeutics (ANIK) is a hidden growth story in the biotech arena. Since ANIK represents a potentially good opportunity, I featured the company this week at Rx Investors. click to enlargeComplete Story » seekingalpha.com |
FDA Panel Backs Novartis MS Drug An FDA panel unanimously said a proposed Novartis drug that would treat multiple sclerosis was safe and effective. online.wsj.com |
Obama's Medicare Pick to Be Installed Obama plans to install his nominee to oversee Medicare and Medicaid, Dr. Donald Berwick, using a tactic aimed at averting a bitter fight in Congress. online.wsj.com |
JOHNSON'S® Brand Launches JOHNSON'S® NATURAL™ Product Line for Babies and Kids - Video SKILLMAN, N.J., Aug. 26 /PRNewswire/ -- JOHNSON'S® Brand, the leading expert in baby skincare, introduces JOHNSON'S® NATURAL™, a line of products that naturally and gently care for baby's skin and hair featuring at least 98 percent plant and fruit-derived natural ingredients. The new line supports the needs of a growing number of moms looking for natural products as part of a natural lifestyle. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/johnsons/45901/ JOHNSON'S® NATURAL™ product line is formulated with a unique combina feedproxy.google.com |
Update on Savient, Chelsea Therapeutics Peter Navarro submits:Several weeks ago, I published a special report on biotech stocks in Seeking Alpha that highlighted, among others, Savient Pharmaceuticals and Chelsea Therapeutics. Here is an important update. Savient Pharmaceuticals (SVNT) is a classic “orphan drug” play on the treatment of severe gout. It did indeed receive its FDA approval for Krystexxa as I predicted. It also jumped from $14 to $20, again exactly as predicted.Complete Story » seekingalpha.com |